ABBV
AbbVie Inc.
ABBV has a slight edge over OSCR overall, supported by lower modeled downside.
OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
ABBV Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Stable |
ABBV's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ABBV PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $294 | — |
| Cheap | 21x | $121 | -59% |
| Fair | 38x | $220 | -25% |
| Current | 51x | $294 | — |
| Expensive | 81x | $473 | +61% |
Historical ranges are pointers, not guarantees.
ABBV's PE is 51x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ABBV in the historical PE scenario, which offers more potential upside but is not a forecast.
ABBV Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for ABBV, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ABBV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $15.81 | +172% |
| Q3 2026 | $5.81 | +340% |
| Q2 2026 | $3.54 | +69% |
| Q1 2026 | $2.03 | -14% |
| Q4 2025 | $2.36 | -1.7% |
| Q3 2025 | $1.32 | -54% |
| Q2 2025 | $2.10 | -30% |
| Q1 2025 | $2.35 | -30% |
| Q4 2024 | $2.40 | -12% |
ABBV earned $5.81 per share over the past year, about four times what it earned the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ABBV on earnings, with more consistent year-over-year improvement.
ABBV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $17.4B | +10% |
| Q2 2026 | $17B | +10% |
| Q1 2026 | $15B | +12% |
| Q4 2025 | $16.6B | +10% |
| Q3 2025 | $15.8B | +9.1% |
| Q2 2025 | $15.4B | +6.6% |
| Q1 2025 | $13.3B | +8.4% |
| Q4 2024 | $15.1B | +5.6% |
ABBV's revenue has grown year over year for 11 quarters in a row: $17.4B last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 36% | +24 points |
| Q2 2026 | 38% | +6.1 points |
| Q1 2026 | 27% | -1.4 points |
| Q4 2025 | 27% | +37 points |
| Q3 2025 | 12% | -14 points |
| Q2 2025 | 32% | +4.1 points |
| Q1 2025 | 28% | +5.3 points |
| Q4 2024 | -9.9% | -32 points |
ABBV has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ABBV on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ABBV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $7.3B | +10% |
| Q2 2026 | $3.1B | -36% |
| Q1 2026 | $3.6B | +155% |
| Q4 2025 | $4.9B | -28% |
| Q3 2025 | $6.6B | +28% |
| Q2 2025 | $4.9B | +141% |
| Q1 2025 | $1.4B | -64% |
| Q4 2024 | $6.8B | +49% |
ABBV's free cash flow has been positive every quarter for seven years: $18.9B over the past year, down 4.1% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ABBV on cash flow, with more consistent year-over-year improvement.
ABBV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +1M shares |
| 1 year | 0% | -- |
| 3 years | +0.1% | +1M shares |
| 5 years | -0.3% | -5M shares |
| Available history | +19% | +288M shares |
ABBV has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5M |
| Q2 2026 | $9M |
| Q1 2026 | $1.5B |
| Q4 2025 | $3M |
| Q3 2025 | $4M |
| Q2 2025 | $12M |
| Q1 2025 | $961M |
| Q4 2024 | $358M |
ABBV spent $1.5B buying back its own shares over the past year, up 13% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ABBV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.4x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 2.7x | Moderate |
| Q3 2025 | 3.6x | Elevated |
| Q2 2025 | 3.3x | Elevated |
| Q1 2025 | 3.5x | Elevated |
| Q4 2024 | 3.5x | Elevated |
ABBV's net debt is about 2.4 years of its operating earnings (EBITDA), down from 3.6 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ABBV on leverage, with a lower net debt burden relative to earnings.
ABBV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.4 | Overbought |
| Stochastic | 86.7 | Overbought |
ABBV's weekly RSI is 71 (overbought) and its Stochastic is 87 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ABBV PE vs Healthcare Sector
| Metric | ABBV | Sector median | Relative |
|---|---|---|---|
| PE | 51x | 26x | 96% above |
| PE % | 64 | 29 | 35 pts above |
ABBV is trading at 51x earnings, a 96% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ABBV on valuation relative to its sector.
ABBV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $281.9 | 4.4% above |
| 20 week MA | $266.1 | 11% above |
| 50 week MA | $238.2 | 24% above |
| 100 week MA | $219.0 | 34% above |
| 200 week MA | $190.8 | 54% above |
ABBV is in an uptrend: it's above all five of its weekly moving averages, and 54% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
ABBV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $89.2 | $103.3 | +16% |
| 2021 | $103.3 | $133.1 | +29% |
| 2022 | $133.1 | $163.1 | +23% |
| 2023 | $163.1 | $155.0 | -5% |
| 2024 | $155.0 | $178.0 | +15% |
| 2025 | $178.0 | $230.0 | +29% |
| 2026 YTD | $230.0 | $294.5 | +28% |
ABBV has finished higher in five of the last six years. It's up 28% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ABBV on returns for 2026, with the stronger performance.